Skip to content
MarketScale
‹ Back to IndustriesHealthcare

An App Could Change How Obesity is Assessed

The idea that something still widely used in the medical world is outdated is an unnerving thought. However, such is the case with the Body Mass Index (BMI), although this appears to be coming to an end. After more than a decade of research, Richard Barnes, CEO of Malvern, England-based Select Research and partners…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The idea that something still widely used in the medical world is outdated is an unnerving thought. However, such is the case with the Body Mass Index (BMI), although this appears to be coming to an end.

After more than a decade of research, Richard Barnes, CEO of Malvern, England-based Select Research and partners at the Mayo Clinic in the U.S. have unveiled an antidote to the 1830s measurement tool that is BMI.

Mayo Clinic Research Associate Dr. Jose Medina-Inojosa, M.D. and Barnes believe Body Volume Index (BVI) is a much better determinant of whether someone is at risk for cardiovascular diseases and diabetes.

“[BMI] is not the complete picture and it’s designed for population statistics. So, for it to be used for an individual assessment of risk is, I believe, inappropriate,” Barnes said. “Yet, to be fair, there hasn’t been anything else available until now.”

What Barnes is calling Body Volume Indicator takes an individual person’s body and measures weight in seven segments as opposed to simply height and weight. This should better determine how at-risk an individual is, giving doctors a clearer course of action and potentially saving clients money on premiums.

The progression of personal technology has been critical to this innovation. Users have photos taken of themselves on a smart device and the software analyzes the images. People have become much more comfortable with this as technology has become a larger part of daily life in the past 10 years, according to Barnes.

“I can’t stress strongly enough the smartphone has allowed us to deliver that in a way we weren’t able to before,” Barnes said. “BMI is just height and weight and that simplicity always meant people had an excuse not to migrate to something else.”

Dr. Medina said the development will help hospitals integrate data on specific patients to the electronic health record system and support the growing field of telemedicine.

“I’m very hopeful this will ease the workload and help the actual face-to-face interactions between the practitioner and the patient,” he said.

The BVI app is currently available in the app store on Android and iOS to provide a demonstration. In the coming months the goal is that a number can be associated with pictures to appropriately assess risk.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512